Hologic division Cynosure has released the US Food and Drug Administration (FDA) cleared advanced Tempsure Envi radiofrequency device for aesthetic skin care.
The device has been designed to reduce fine facial lines and wrinkles, tighten skin with soft tissue coagulation, and improve cellulite appearance.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
TempSure Envi works by heating the skin’s deep layers to regenerate collagen as well as improve the appearance of cellulite and wrinkles that appear on the forehead, mouth and eyes.
Claimed to be suitable for any type of skin, treatment with the device ranges from 30 to 60 minutes, depending on the target area.
The device features the Therapeutic Logic Control (TLC) system that facilitates consistent treatment temperatures and better patient comfort levels by connecting treatment time with the target temperature.
Hologic Cynosure division president Kevin Thornal said: “With a customer base looking to diversify their specialty offerings beyond laser and injectable treatments, we are enthusiastic about the opportunity to provide a radiofrequency platform as effective and versatile as TempSure Envi.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We also look forward to a variety of future TempSure FDA clearances, including surgical and women’s health capabilities, among others, meeting additional critical customer needs.”
Cynosure develops and manufactures various light-based aesthetic and medical treatment systems for different applications such as scar reduction, hair removal, skin revitalisation, and vascular lesions treatment.
In addition to TempSure Envi, the firm’s portfolio comprises multiple products, including Accolade, Cellulaze, Emerge, Icon, PelleFirm RF Body Treatment System, and SculpSure.
